Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 1.00 |
| ▸ | TUBB | P07437 | 2/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 2/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 2/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 2/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 2/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 2/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 8/20 | 0.76 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.76 |
| ▸ | NQO2 | P16083 | 4/20 | 0.76 |
| ▸ | TTR | P02766 | 1/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7Z-3,4,4'-Trimethoxystilbene SCHEMBL2948082 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| 7Z-3,4,4'-Trimethoxystilbene SCHEMBL9188558 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9173364 | 0.92 | CYP1A1 (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9173377 | 0.92 | CYP1A1 (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9586847 | 0.89 | CYP1A1 (0.80) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9431599 | 0.89 | CYP1A1 (0.80) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| (E)-3,4,3',5'-Tetramethoxystilbene SCHEMBL1394570 | 0.86 | CYP1A1 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3750347 | 0.86 | CYP1A1 (0.93) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15785978 | 0.86 | CYP1A1 (0.93) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| (E)-3,4,3',5'-Tetramethoxystilbene SCHEMBL1394568 | 0.86 | CYP1A1 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11229660-B2 | Glycan therapeutics and method of treating conditions associated with TMAO | KALEIDO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210137956-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210113596-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10881676-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10702542-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200093845-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| WO-2013147630-A1 | METHOXY AND METHYLTHIO DERIVATIVES OF TRANS-STILBENE AND THEIR USE | UNIWERSYTET MEDYCZNY IM. KAROLA MARCINKOWSKIEGO (PL) | 2013-10-03 | — | — | WO | disclosed |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | STC.UNM (US) | 2013-07-11 | — | — | US | disclosed |
| US-7759527-B2 | Microwave induced one pot process for the preparation of arylethenes | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-07-20 | — | — | US | disclosed |
| WO-2008070872-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080045752-A1 | Microwave Induced One Pot Process For The Preparation Of Arylethenes | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-02-21 | — | — | US | disclosed |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2007-10-25 | — | — | US | disclosed |
| WO-2007110881-A1 | A MICROWAVE INDUCED ONE POT PROCESS FOR THE PREPARATION OF ARYLETHENES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2007-10-04 | — | — | WO | disclosed |
| US-5430062-A | Combretastatin analogues; inhibition of tubulin polymerization and colchicine binding; antitumor,-mitotic and -neoplastic agents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0641301-A1 | STILBENE DERIVATIVES AS ANTICANCER AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023357-A1 | STILBENE DERIVATIVES AS ANTICANCER AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045752-A1 | Microwave Induced One Pot Process For The Preparation Of Arylethenes | TET2, HCN4, KDM4E | TUBB4A 1651/4885TUBB 1381/4885TUBA3C 2163/4885 |
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | TUBB4A 1105/4885TUBB 488/4885TUBA3C 1552/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | TUBB4A 1300/4885TUBB 594/4885TUBA3C 1483/4885 |
| US-20070249647-A1 | Substituted CIS- and trans-stilbenes as therapeutic agents | TGFB1, VHL, TMSB10 | TUBB4A 144/4885TUBB 58/4885TUBA3C 663/4885 |
| US-20130178536-A1 | SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS | PSEN1, TERT, PSEN2 | TUBB4A 271/4885TUBB 196/4885TUBA3C 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.